NRC HEALTH NRC

Industrials SIC 8731 - Services-Commercial Physical & Biological Research NAICS Professional, Scientific, and Technical Services › Scientific Research and Development Services › Research and Development in the Physical, Engineering, and Life Sciences › Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) derived Nasdaq

Last close 21.93 2026-10-23
Market cap $485.1M 2026-06-30 share count
52-week range 11.32 - 23.68

Valuation FY2025 figures against the last close

P/S3.5x
P/E0.4x
P/FCF30.8x
EV/EBITDA24.6x
Dividend yield2.3%
Diluted EPS50.00

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $137.4M$143.1M$148.6M$151.6M$148.0M$133.3M$128.0M$119.7M$117.6M$109.4M
SG&A $54.8M$44.9M$46.6M$42.7M$39.0M$34.4M$33.0M$31.4M$29.7M$28.4M
Total operating expenses $114.8M$107.9M$108.5M$105.0M$97.7M$91.1M$84.9M$84.4M$83.3M$78.2M
Operating income $22.6M$35.2M$40.0M$46.5M$50.3M$42.7M$43.0M$35.3M$34.2M$31.2M
Interest expense $4.8M$2.6M$862.0K$1.2M$1.7M$1.8M$2.1M$1.5M$82.0K$190.0K
Pre-tax income $17.8M$32.7M$40.0M$42.8M$48.6M$41.5M$40.5M$34.7M$34.3M$31.4M
Income tax $6.2M$7.9M$9.0M$11.0M$11.2M$4.2M$8.1M$4.7M$11.3M$10.8M
Net income $11.6M$24.8M$31.0M$31.8M$37.5M$37.3M$32.4M$30.0M$22.9M$20.5M
EPS, basic 50.001.051.261.281.471.481.30———
EPS, diluted 50.001.041.251.271.461.451.26———
Shares, diluted (wtd. avg.) 22.4M23.7M24.7M25.1M25.6M25.7M25.7M———

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $4.1M$4.2M$6.7M$25.0M$54.4M$34.7M$13.5M$13.0M$34.7M$33.0M
Receivables $11.1M$11.1M$12.4M$14.5M$13.7M$13.9M$11.6M$11.9M$14.8M$10.9M
Total current assets $20.2M$19.6M$24.4M$43.7M$73.7M$54.1M$29.2M$28.4M$52.3M$47.1M
Property, plant and equipment ——$28.2M$17.2M$12.4M$11.7M$13.5M$14.2M$12.4M$11.8M
Goodwill $66.2M$66.2M$61.6M$61.6M$61.6M$57.3M$57.9M$57.8M$58.0M$57.9M
Other intangibles $2.2M$2.6M$1.5M$1.6M$1.8M$1.4M$1.7M$2.1M$2.8M$3.1M
Total assets $134.9M$132.5M$122.4M$130.5M$157.5M$133.4M$110.7M$108.0M$127.3M$120.6M
Accounts payable $1.2M$1.2M$1.3M$1.2M$1.9M$1.1M$1.3M$613.0K$593.0K$765.0K
Short-term debt ————————$1.1M$2.7M
Total current liabilities $36.6M$35.9M$36.2M$33.4M$40.4M$31.7M$38.2M$47.1M$32.3M$31.5M
Long-term debt $75.0M$57.9M$29.5M$22.3M$26.6M$30.7M$29.8M$34.2M$1.1M$857.0K
Total liabilities $120.9M$101.3M$73.5M$58.4M$72.2M$69.1M$77.8M$88.9M$37.3M$37.8M
Retained earnings -$17.3M-$17.1M-$30.5M-$25.2M-$36.1M-$61.4M-$93.4M-$106.3M$77.6M$71.5M
Total equity $14.0M$31.3M$49.0M$72.0M$85.3M$64.3M$32.9M$19.1M$90.0M$82.8M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $26.4M$34.6M$38.1M$36.3M$46.3M$40.6M$40.9M$39.8M$28.1M$26.8M
Stock-based compensation $3.3M$284.0K$935.0K$1.2M$623.0K$680.0K$1.2M$1.5M$1.8M$1.9M
Capital expenditure $10.7M$15.4M$15.8M$9.8M$5.5M$4.0M$4.7M$6.0M$4.6M$4.0M
Investing cash flow -$10.7M-$20.3M-$15.8M-$9.8M-$8.5M-$3.7M-$4.7M-$6.0M-$6.1M-$3.8M
Financing cash flow -$15.8M-$16.8M-$40.7M-$55.6M-$18.2M-$15.5M-$36.3M-$54.5M-$21.1M-$32.5M
Dividends paid $11.0M$11.5M$36.4M$21.0M$9.2M$10.5M$31.3M$16.9M$16.9M$28.6M
Buybacks $20.2M$30.9M$19.1M$27.6M$4.1M$10.0M$4.7M$8.0M$4.1M$601.0K

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001437749-26-015775.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. 0 50M 100M 150M 200M Revenue, FY2016: 109.4M Net income, FY2016: 20.5M Revenue, FY2017: 117.6M Net income, FY2017: 22.9M Revenue, FY2018: 119.7M Net income, FY2018: 30M Revenue, FY2019: 128M Net income, FY2019: 32.4M Revenue, FY2020: 133.3M Net income, FY2020: 37.3M Revenue, FY2021: 148M Net income, FY2021: 37.5M Revenue, FY2022: 151.6M Net income, FY2022: 31.8M Revenue, FY2023: 148.6M Net income, FY2023: 31M Revenue, FY2024: 143.1M Net income, FY2024: 24.8M Revenue, FY2025: 137.4M Net income, FY2025: 11.6M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $109.4M $117.6M $119.7M $128.0M $133.3M $148.0M $151.6M $148.6M $143.1M $137.4M
Gross profit — — — — — — — — — —
Net income $20.5M $22.9M $30.0M $32.4M $37.3M $37.5M $31.8M $31.0M $24.8M $11.6M

Recent filings and events

  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Officer or director change Item 5.02
  • Officer or director change Item 5.02
  • Charter or fiscal year changed Item 5.03
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Results announced Item 2.02
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 8731

TickerCompanyMarket capP/ERevenue growth
IQV IQVIA HOLDINGS INC. $46.63B 35.6x 5.9%
INCY INCYTE CORP $23.12B 18.1x 21.2%
MEDP Medpace Holdings, Inc. $18.68B 43.8x 20.0%
CRL CHARLES RIVER LABORATORIES INTERNATIONAL, INC. $16.49B — -0.9%
ABSI Absci Corp $1.58B — -38.2%
OABI OmniAb, Inc. $677.5M — -29.3%
ONMD OneMedNet Corp $279.2M — 111.4%
MXCT MAXCYTE, INC. $144.5M — -5.7%